10-Q quarterly report · filed Nov 5, 2026

Cartesian Therapeutics, Inc. (RNAC) Q3 2026 10-Q Quarterly Report

Short answer

Cartesian Therapeutics, Inc. (RNAC) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$11M.

Q3 2026 key financials · XBRL

Revenue
$0
Net income
−$11M
+68.0% YoY · −172.8% QoQ
EPS (diluted)
−$0.38
+72.5% YoY · −160.3% QoQ

Source: XBRL data from the Cartesian Therapeutics, Inc. (RNAC) Q3 2026 10-Q on SEC EDGAR. USD.

Cartesian Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0 vs $0.5M, down 100% YoY, reflecting no grant revenue
  • Net loss $11.5M vs $35.9M, operating loss $25.0M vs $21.1M YoY
  • R&D $15.6M, up $1.8M, led by Descartes-08 MG at $6.5M vs $5.4M
  • Cash, equivalents and restricted cash $124.7M, operating cash use $70.9M for nine months
  • Financing provided $69.6M, including $46.0M term-loan proceeds and $22.8M ATM proceeds
  • Outlook: continued losses and higher R&D spending, funding runway at least 12 months, additional financing required

Risk Factors

  • New dilution risk: equity issuance or Loan Agreement conversions could reduce ownership and depress common-stock price
  • New debt-covenant risk: May 2026 K2HV Loan Agreement secured substantially all assets, excluding intellectual property
  • Liquidity risk: minimum unrestricted cash requirement equals 80% of lender obligations beginning April 1, 2027
  • Commercial risk: $40.0 million trailing three-month net product revenue covenant begins January 1, 2029
  • Default risk: K2HV may accelerate obligations after an event of default, potentially exceeding available cash

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Cartesian Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.